NeuroScientific Biopharmaceuticals Limited (ASX:NSB)
Australia flag Australia · Delayed Price · Currency is AUD
0.0540
+0.0010 (1.89%)
May 14, 2025, 11:15 AM AEST

ASX:NSB Cash Flow Statement

Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2016 - 2019
Period Ending
Dec '24 Jun '24 Jun '23 Jun '22 Jun '21 Jun '20 2016 - 2019
Net Income
1.190.32-1.07-10.44-3.18-2.87
Upgrade
Depreciation & Amortization
0.090.090.060.060.060.06
Upgrade
Stock-Based Compensation
0.130.130.241.350.630.5
Upgrade
Other Operating Activities
0.25-----
Upgrade
Change in Accounts Receivable
-0.01-0.010.08-0.07-0.030.01
Upgrade
Change in Accounts Payable
-0.5-0.5-1.581.990.110.02
Upgrade
Change in Other Net Operating Assets
0.010.01-0.030.16-0.190.01
Upgrade
Operating Cash Flow
1.160.04-2.3-6.94-2.6-2.28
Upgrade
Capital Expenditures
--0--0-0.03-0
Upgrade
Investing Cash Flow
--0--0-0.03-0
Upgrade
Issuance of Common Stock
----13.320.96
Upgrade
Other Financing Activities
----0.18-
Upgrade
Financing Cash Flow
----13.510.96
Upgrade
Net Cash Flow
1.160.04-2.3-6.9510.88-1.32
Upgrade
Free Cash Flow
1.160.04-2.3-6.95-2.63-2.28
Upgrade
Free Cash Flow Margin
52.30%1.92%-46.52%--274.46%-
Upgrade
Free Cash Flow Per Share
0.01--0.02-0.05-0.02-0.03
Upgrade
Levered Free Cash Flow
0.64-0.19-1.97-3.08-1.49-1.26
Upgrade
Unlevered Free Cash Flow
0.64-0.18-1.97-3.08-1.49-1.25
Upgrade
Change in Net Working Capital
0.110.51.54-2.080.11-0.03
Upgrade
Updated Feb 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.